Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

Inhibitory Effect of Monoclonal Antibodies Against CXCR3-B NH2-Terminus on the Proliferation of U937 Cells.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4

Mouse Anti-Human CXCR3 Mab Preparation and Its Biological Function

CXCR3-binding chemokines: novel multifunctional therapeutic targets

Characterization and Application of Two Novel Monoclonal Antibodies Against Human Cxcr4: Cell Proliferation and Migration Regulation for Glioma Cell Line in Vitro by Cxcr4/Sdf-1 Alpha Signal

Structural insights into the activation and inhibition of CXC chemokine receptor 3

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

Preparation and Characterization of a New Monoclonal Antibody Against CXCR4 Using Lentivirus Vector.

A Novel Blocking Monoclonal Antibody Recognizing a Distinct Epitope of Human CD40 Molecule.

CX3CR1 Positively Regulates BCR Signaling Coupled with Cell Metabolism Via Negatively Controlling Actin Remodeling

A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection

Multivalent CXCR4-targeting nanobody formats differently affect affinity, receptor clustering, and antagonism

Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping.

Human C-C Chemokine Receptor 3 Monoclonal Antibody Inhibits Pulmonary Inflammation in Allergic Mice

In Vitro Immunological Effects of CXCR3 Inhibitor AMG487 on Dendritic Cells.

Transfection of Colorectal Cancer Cells with Chemokine MCP-3 (monocyte Chemotactic Protein-3) Gene Retards Tumor Growth and Inhibits Tumor Metastasis

CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma

Generation and Characterization of a New Monoclonal Antibody Against CXCL4

Cxcr3 Expression on Cd34(+) Hemopoietic Progenitors Induced by Granulocyte-Macrophage Colony-Stimulating Factor: Ii. Signaling Pathways Involved